Investor profile
Pfizer Ventures has backed 17 European tech companies across 23 funding rounds between 2016 and 2026, joining rounds totalling €890M. Most active in Healthtech and Fintech. Data as of 7 Aug 2026.
Also recorded as: Pfizer · Pfizer Venture Investments
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Anaveon | Switzerland | 1 | €105M |
| Imcheck Therapeutics | France | 2 | €103M |
| Artios | UK | 1 | €99M |
| Immunos Therapeutics | Switzerland | 3 | €92M |
| Grey Wolf Therapeutics | UK |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Anaveon | Series B | €105M | 2021-12 |
| Artios | Series D+ | €99M | 2025-11 |
| Immunos Therapeutics | Series B | €68M | 2022-06 |
| Imcheck Therapeutics |
| 2 |
| €87M |
| Storm Therapeutics | UK | 2 | €76M |
| Anjarium Biosciences | Switzerland | 1 | €51M |
| Vivet Therapeutics | France | 1 | €45M |
| FoRx Therapeutics | Switzerland | 1 | €43M |
| Agomab Therapeutics | Belgium | 1 | €41M |
| Nucleome Therapeutics | UK | 1 | €38M |
| Enara Bio | UK | 1 | €29M |
| Trimtech Therapeutics | UK | 1 | €29M |
| MISSION Therapeutics | UK | 2 | €25M |
| Metabomed | Israel | 1 | €16M |
| Amra | Sweden | 1 | €8.2M |
| VitaDAO | Germany | 1 | €3.8M |
| Other |
| €54M |
| 2020-09 |
| Anjarium Biosciences | Series A | €51M | 2021-09 |
| Imcheck Therapeutics | Series B | €49M | 2019-10 |
| Storm Therapeutics | Series C | €48M | 2026-04 |
| Vivet Therapeutics | Other | €45M | 2019-01 |
| Grey Wolf Therapeutics | Series B | €45M | 2023-01 |
| FoRx Therapeutics | Series A | €43M | 2025-12 |
